

Symposia Schedule of Events

Please note some presentations are requesting pre-registration. Those links are provided in the session listings below if applicable.

Tuesday, September 8, 2020

9–10 am EST

NERLYNX® (neratinib) for Patients with HER2+ Breast Cancer: Strategies and Support Tools to Achieve Durable Therapy

Puma Biotechnology

Please join us for this educational program on Tuesday, September 8th at 9:00 AM to learn more about NERLYNX® (neratinib) for HER2+ Breast Cancer including how to anticipate and mitigate TKI adverse events. Our nurse oncology expert will share data on NERLYNX and strategies to equip you and your practice to support these high-risk patients on TKI therapy.

5–6 pm EST

Advances in Hemophilia A: Coordinating Care Through Effective Communication and Therapy Selection

1 Contact Hour

This continuing nurse education activity is provided by Vindico Medical Education.

Join Regina B. Butler, RN-BC; James E. Munn MS, BS, BSN, RN-BC; and Kerry Hansen RN, BSN on Tuesday, September 8 at 5 PM EDT for a CNE Virtual Symposium with live Q & A. They will assess the latest evidence regarding treatments for patients with hemophilia A, provide guidance on identifying patients without factor VIII inhibitors who may benefit from newer treatment options, and discuss strategies to promote shared decision-making and improve patient satisfaction.

New Strategies for Multiple Myeloma Care: Case Studies for Nurses

1 Contact Hour

REGISTER HERE: <https://imf-ons.myeloma.org/>

This activity is supported by educational grants from Bristol Myers Squibb (formerly Celgene); Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.

Multiple myeloma care is rapidly evolving with new agents and combinations, new testing, and risk-adapted treatment strategies. Four highly experienced nurses will share their expertise during this 1.5 CNE symposium (3 sessions of 0.5 CNE) while using real-life patient case scenarios to focus on symptom management, infection control, and nursing implications. The

participants can take part in a single session, two sessions, or the entire symposium. Free downloadable tools and resources are provided.

Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment Landscape

Astellas

Join us to learn about

- An overview of the mCSPC disease state
- The efficacy and safety profile of XTANDI in mCSPC
- XTANDI dosing and administration

Thursday, September 10, 2020

9–10 am EST

CAR T-CELL THERAPY: A ROAD MAP FOR NURSES

1 Contact Hour

REGISTER HERE: www.LLS.org/ONSBridge2020

This session is provided by The Leukemia & Lymphoma Society with support from Bristol Myers Squibb Company, Kite, A Gilead Company and Novartis Pharmaceuticals Corporation

Nurses from three cancer centers will discuss the nurse's role in preparing patients and caregivers for the CAR T-cell treatment process, assessment, monitoring for and managing side effects, and communication with the patient's community healthcare team to transition patient care. Following a patient from initial treatment discussion, symposium attendees will be able to provide feedback on patient care for the case, in this interactive session. With CAR T therapy and follow-up care expanding beyond the major centers, nurses are essential members of the treatment team.

Treatment of patients in newly diagnosed multiple myeloma

Patient adherence and dose modifications in response to adverse events

BMS Multiple Myeloma

This program will share information about a treatment option for newly diagnosed multiple myeloma including the impact of multiple myeloma on patients, dose modifications for consideration due to adverse events, and approaches to keep patients on therapy.

- Multiple myeloma disease impact
- Information about a treatment option for patients with NDMM
- Disease impact of multiple myeloma
- Dose modifications due to adverse events
- Patient education and resources

Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine

1 Contact Hour

Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from AstraZeneca.

Let us buy your lunch after the meeting! Receive a GrubHub credit for attending this presentation and receive 1.0 ANCC credit. Participants will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse's role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations. This presentation will also explore strategies to improve communication between nurses and patients/caregivers in an effort to promote shared decision-making, reduce adverse events, and improve adherence. In Partnership with LUNGeivity Foundation

Tuesday, September 15, 2020

9–10 am EST

CAR T Cell Therapy: The Science and Patient Journey

Bristol Myers-Squibb CAR-T

Learn more about the potential of CAR T cell therapy. This presentation will help you understand the science behind this novel immunotherapy and its ability to fight certain cancers. You'll learn about the CAR T cell therapy patient journey, as well as the multidisciplinary treatment team that supports them. The presentation will close with how to monitor and manage select side effects of treatment.

Thursday, September 17, 2020

9–10 am EST

Immunotherapy for Multiple Myeloma: From Antibodies to CAR T-Cell Therapy

1 Contact Hour

REGISTER HERE: <https://education.redmeded.com/a/RJXBAM>

Jointly provided by the Multiple Myeloma Research Foundation, Purdue University Continuing Nursing Education, and RedMedEd. Support for this activity has been provided through educational grants from Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Sanofi Genzyme.

Multiple myeloma remains incurable, but the number and type of treatments continue to expand rapidly. A development that holds particular promise for patients with relapsed/refractory myeloma is the emergence of immunotherapy options such as antibody-based therapies, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapy. Successful implementation of myeloma immunotherapy into practice, however, requires



oncology nurses and advanced practitioners to be current on new and emerging immunotherapeutic agents and strategies. This webcast will provide information on the newest myeloma immunotherapy treatments, including their rationale for use and results from ongoing clinical studies. There is no fee for attending this activity. At the conclusion of the activity, participants must complete an evaluation and credit request. Certificates will be emailed approximately 4 weeks after participation.

Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape

1 Contact Hour

Presented by Creative Educational Concepts (CEC) and supported by an independent educational grant from AstraZeneca.

Let us buy your lunch after the meeting! Receive a GrubHub credit for attending this presentation and 1.0 ANCC credit. This symposium will review the rationale for targeting the B-cell receptor (BCR) pathway in CLL and its role in tumor proliferation. There will also be discussion regarding the latest safety and efficacy data for BTK inhibitors in CLL based on line of therapy, cytogenetics, and other patient-/disease-specific factors, latest guidelines, as well as identification of patients that would derive benefit from BTK inhibitor therapy. Attendees of this virtual symposium will also gain knowledge about the differences between available BTK inhibitors and how to quickly recognize and appropriately manage adverse events that may arise with therapy. The final portion of the presentation will be interactive and focus on applying the latest evidence into clinical practice by discussing CLL/SLL patient cases and the various challenges faced by clinicians managing patients with BTK inhibitors. There will also be discussion on how BTK inhibitor can be of potential benefit for patients at risk or who contract COVID-19.

5–6 pm EST

A Case-based Discussion on Improving Outcomes in Patients With Newly-Diagnosed secondary AML

REGISTER HERE: <https://www.surveymonkey.com/r/2020ONS>

Jazz Pharmaceuticals

- t-AML and AML-MRC: Presentation, risks, and clinical considerations
- Treatment for adults with newly diagnosed t-AML or AML-MRC
- Key issues for nurses: Managing AML treatment complications and supporting the patient through counseling and education
- Critical decision points in care: Dialog on the essential role of the nurse

Visit the RTP [archived webinars](#) slide site to review related topics presented in conjunction with the ONS Bridge Conference.